According to the official website of the State Food and drug administration, on March 1, the State Food and Drug Administration conditionally approved the application for registration of recombinant novel coronavirus protein vaccine (CHO cells) of Anhui zhifeilong Kema biopharmaceutical Co., Ltd. The vaccine is the first approved domestic recombinant novel coronavirus protein vaccine, which is suitable for preventing diseases caused by novel coronavirus infection (covid-19). According to the relevant provisions of the vaccine administration law and the drug administration law, the State Food and Drug Administration conducts emergency review and approval according to the special drug approval procedures, and approves the application for registration of the vaccine with conditions. The State Food and drug administration requires the holder of the marketing license of the vaccine to continue to carry out relevant research work, complete the conditional requirements, and timely submit the follow-up research results. According to the data, Wu Liangyou, deputy director of the disease control bureau of the National Health Commission, said at the press conference of the joint prevention and control mechanism of the State Council held on February 19 that recently, with the approval of the joint prevention and control mechanism of the State Council, the National Health Commission has begun to deploy the sequential strengthening of immunization. Previously, the target population over 18 years old who had been vaccinated with inactivated vaccines of Sinopharm Zhongsheng Beijing company, Wuhan company, Beijing Kexing company and adenovirus vector vaccine of Tianjin kangxinuo company for 6 months or more could be immunized with one dose of hypologous booster, that is, with the original vaccine. After the implementation of the sequential booster immunization strategy, the target population who have been vaccinated with the above three inactivated vaccines in the whole process can also choose the recombinant protein vaccine of zhifeilong KOMA or the adenovirus vector vaccine of kangxinuo for sequential booster immunization. Wu Liangyou said that for the target population, one of homologous enhanced immunization and sequential enhanced immunization can be selected. In addition, the joint prevention and control mechanism of the State Council also approved the homologous enhanced immunization of inactivated novel coronavirus vaccine of Kangtai company and Institute of biology of medical college. Both homologous enhancement and sequential enhancement were implemented in people over 18 years old who had completed the whole course of vaccination for 6 months. (outlook new era)
Edit：Yuanqi Tang Responsible editor：Xiao Yu
Source：
Special statement: if the pictures and texts reproduced or quoted on this site infringe your legitimate rights and interests, please contact this site, and this site will correct and delete them in time. For copyright issues and website cooperation, please contact through outlook new era email：lwxsd@liaowanghn.com
Recommended Reading Change it 
Home
